Clene (CLNN) CEO On Biopharmaceutical Company & Earnings Beat

<p>Clene (CLNN) stock was up around 3% today. Recent earnings report indicated $0.42 in EPS and $110K in revenue, beating estimates. CEO, Rob Etherington, says that the biopharmaceutical company focuses on neurodegenerative diseases. What are the plans for the company's future growth, and how will the CLNN stock price continue to perform?</p><p><br></p>